ArvinasARVN +2.56%70 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates ARVN with a GF Score™ of 70/100 and a GF Value™ of $11.91 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 703 Biotechnology companies, Arvinas ranks worse than 142247.37% on this metric.
The historical rank and industry rank for Arvinas's Days Payable or its related term are showing as below:
ARVN's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76 * Ranked among companies with meaningful Days Payable only.
Arvinas's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Arvinas Days Payable Related Terms
Arvinas Days Payable Historical Data
* Premium members only.
The historical data trend for Arvinas's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arvinas's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arvinas Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arvinas's Days Payable distribution charts can be found below:
* The bar in red indicates where Arvinas's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Arvinas's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arvinas (ARVN) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arvinas and its competitors. According to the industry distribution chart, Arvinas ranks #999999 out of 703 companies in the Biotechnology industry.
Is Arvinas' Days Payable too high?
Arvinas' current Days Payable is 0.00. Based on the distribution chart, Arvinas ranks #999999 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arvinas has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arvinas' Days Payable compare to ZURA and KYTX?
According to the Biotechnology industry distribution chart, Arvinas ranks #999999 out of 703 companies for Days Payable. This places Arvinas in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arvinas and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arvinas's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arvinas stock overvalued right now?
Based on GuruFocus' analysis, Arvinas (ARVN) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.91, compared to a current price of $8.41 — trading 29.4% below its estimated fair value. The current Days Payable is 0.00. Arvinas' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Arvinas (ARVN), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arvinas (ARVN) Overvalued in 2026?
Based on GuruFocus' analysis, Arvinas stock appears to be undervalued.
The current stock price of $8.41 is trading 29.4% below its estimated GF Value™ of $11.91.
GuruFocus considers Arvinas to be Modestly Undervalued.
Key valuation signals for ARVN:
Days Payable: 0.00
GF Value™: $11.91 vs. price of $8.41 (29.4% below fair value)
No single metric tells the full story. See the ARVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
70GF Score
Get the complete analysis for ARVN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARVN has been successfully added to your 
